Recent results from Icahn School of Medicine at Mount Sinai researchers have shown that two approved cancer drugs have the capacity to turn on a gene responsible for cancer cells’ dormancy. In the study entitled, “NR2F1 controls tumor cell dormancy via ​SOX9- and ​RARβ-driven quiescence programmes,” published in Nature Communications, the research team found that